Moderna (MRNA) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Moderna Reports First Quarter 2020 Financial Results and Provides Business Updates
May 7, 2020 7:00 AM EDTProgress on novel coronavirus vaccine (mRNA-1273) includes FDA clearance to proceed with Phase 2 study
Finalizing protocol for Phase 3 study of mRNA-1273, expected to begin in early summer of 2020
Awarded up to $483 million funding from BARDA for accelerated development of mRNA-1273
Entered strategic collaboration with Lonza Ltd. to manufacture up to one billion doses of mRNA-1273 per year
Up to $2.4 billion to invest, including cash and investments of $1.7 billion and up to $0.7 billion in potentially available grants and awards; reconfirms... More
